Study #2015-0621
A Multicenter Phase 1, Open-Label, Dose-Escalation Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
DCC-2618
Description
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-227-7897
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.